Regeneron Reports Third Quarter 2026 Financial and Operating Results
Key Highlights
- ➤Q3 revenue $5.1 billion, up 36% year over year
- ➤Non-GAAP EPS $20.07, up 70%; GAAP EPS $18.45, up 35%
- ➤Sanofi collaboration adds $1.0 billion upfront and up to $7.0 billion milestones
- ➤EYLEA HD U.S. sales $699 million, up 62%; Libtayo global sales $550 million, up 51%
- ➤2026 guidance raises R&D and SG&A ranges while lowering capital-expenditure range
Expert Statements
Leonard S. Schleifer, Board co-Chair, President and Chief Executive Officer of Regeneron
“This was an outstanding quarter for Regeneron, with Dupixent, EYLEA HD, and Libtayo each achieving record net sales.”
Leonard S. Schleifer, Board co-Chair, President and Chief Executive Officer of Regeneron
“Our pipeline of about 50 product candidates is rapidly advancing.”
Leonard S. Schleifer, Board co-Chair, President and Chief Executive Officer of Regeneron
“We expect an FDA decision for cemdisiran in generalized myasthenia gravis next month; our Phase 3 programs in multiple myeloma, lymphoma, anticoagulation, and obesity continue to advance; and we have generated encouraging early data in MASH, POTS, and ovarian cancer.”
Leonard S. Schleifer, Board co-Chair, President and Chief Executive Officer of Regeneron
“Finally, we expanded our alliance with Sanofi to include four Regeneron-invented, next-generation, long-acting antibodies designed to build on the success of Dupixent.”
Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron
“We are pleased with our third quarter financial results, which marked our third consecutive quarter of double-digit growth in both revenue and non-GAAP EPS.”
Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron
“Strong commercial execution across our portfolio, together with the anticipated step-up in Sanofi collaboration revenue in the first full quarter following repayment of the Development Balance, drove a 36% increase in total revenues and a 70% increase in non-GAAP EPS, positioning us to deliver one of our strongest years ever.”
* Third quarter 2026 revenues increased 36% to $5.1 billion versus third quarter 2025 * Dupixent(®) global net sales (recorded by Sanofi) increased 35% to $6.5 billion * EYLEA HD(® )U.S. net sales increased 62% to $699 million * Libtayo(®) global net sales increased 51% to $550 million * GAAP EPS increased 35% to $18.45; non-GAAP EPS((a) )increased 70% to $20.07 * Expanded collaboration with Sanofi, adding multiple next-generation, long-acting immunology antibodies; $1.0 billion up-front to be recognized as collaboration revenue in fourth quarter 2026 with potential to receive up to an additional $7.0 billion in future milestones * Pasatru™ (garetosmab) approved by FDA for fibrodysplasia ossificans progressiva (FOP) TARRYTOWN, N.Y., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the third quarter of 2026 and provided a business update.
Get started
Create a free account to read the full story.